Zydus Gets CDSCO Panel Nod To Study Follitropin alfa
New Delhi: The drug major Zydus has got a green signal from the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) to conduct Phase IV study of recombinant human follicle-stimulating hormone, Follitropin alfa.This came after the firm presented the proposal for the conduct of Phase IV clinical trial titled "A Phase IV, single-arm,...
New Delhi: The drug major Zydus has got a green signal from the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) to conduct Phase IV study of recombinant human follicle-stimulating hormone, Follitropin alfa.
Follitropin alfa injection is also used as a fertility medicine to help men with low sperm counts produce more sperm. Treatment with human chorionic gonadotropin should come before treatment with follitropin alfa.
Follitropin alpha (recombinant human follicle-stimulating hormone; follitropin alfa) is a recombinant form of follicle-stimulating hormone (FSH), an endogenous gonadotrophin.
FSH binds to the follicle-stimulating hormone receptor which is a G-coupled transmembrane receptor. The binding of the FSH to its receptor seems to induce phosphorylation and activation of the PI3K (Phosphatidylinositol-3-kinase) and Akt signalling pathway, which is known to regulate many other metabolic and related survival/maturation functions in cells.
At the recent SEC meeting for Reproductive and Urology held on 30th November 2022, the expert panel reviewed the proposal presented by the drug major Zydus to conduct Phase IV clinical trial for the Follitropin alfa (rFSH) Injection in multidose pre-filled glass cartridges (300 IU, 450 IU, 900 IU) or single-use Vial (75 IU).
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd